Indonesian court ruling against pharmaceutical patent evergreening signals global shift, advocates say
Source Summary
An Indonesian court has ruled against "patent evergreening," a practice where pharmaceutical companies extend patent protections to delay generic drug competition. Patient advocates view the decision as a significant precedent that could encourage other countries to challenge similar industry practices. The ruling addresses a key barrier to affordable medication access in developing nations.
Why it matters
The ruling establishes a legal precedent against a practice that restricts access to affordable generic medicines in developing countries, potentially influencing pharmaceutical patent policy globally.
